SR
Shinya Rai
Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Centre for Lymphoid Cancer, British Columbia Cancer
Research areas: Medicine · Pathology and Forensic Medicine · Lymphoma Diagnosis and Treatment · Chronic Lymphocytic Leukemia Research · Viral-associated cancers and disorders
0000-0003-3929-9751
Employment
-
Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine
-
Centre for Lymphoid Cancer, British Columbia Cancer
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (27)
- Data from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes Save
- Supplementary Figures S1-S30 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes Save
- Supplementary Figures S1-S30 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes Save
- Supplementary Tables 1-16 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes Save
- Supplementary Tables 1-16 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes Save
- Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes Save
- Clonal Complexity Defines Distinct Tumor‐Intrinsic Biology and Prognosis in Diffuse Large B‐Cell Lymphoma Save
- Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma Save
- A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma Save
- Depletion of Ppp6c in hematopoietic and vascular endothelial cells causes embryonic lethality and decreased hematopoietic potential Save
- Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma Save
- Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial Save
- Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database Save
- Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL‐6 production in lymphoma cells Save
- Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia Save
- Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma Save
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma Save
- Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial Save
- Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus Bendamustine Save
- A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma Save